| ¿µ¹® | neoplasm | ÇÑ±Û | ½Å»ý¹° |
|---|---|---|---|
| ¼³¸í | »õ·Î »ý±ä ¹°ÁúÀ̶ó´Â ¶æÀÌ´Ù. À̰ÍÀº ´Ù¸¥ ¸»·Î ¡°Á¾¾ç(tumor)¡±À̶ó°íµµ ÇÏ´Â µ¥, ½ÇÁ¦·Î À̵éÀÇ ¸íÈ®ÇÑ ¶æÀº ¼·Î ´Ù¸£´Ù. Á¾¾çÀ̶ó´Â ¸»Àº ¡°±× Å©±â°¡ 1cm°¡ ³Ñ´Â ÀÏÁ¾ÀÇ È¤¡±À» ¸»ÇÏ´Â °ÍÀ¸·Î ÇǺΰú¿¡¼´Â À̺¸´Ù ÀÛÀº ȤÀ» ±¸ÁøÀ̶ó°í ÇÏ¿© ±¸º°ÇÏ¿© ºÎ¸¥´Ù. ÇÏÁö¸¸, À̰ÍÀº ¶ÇÇÑ ÇǺλӸ¸ ¾Æ´Ï¶ó ½Åü³» ¾îµð¿¡¼µç »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ¸ðµÎ ÅëĪÇÏ¿© Á¾¾çÀ̶ó°í ºÎ¸¥´Ù. ÀÌ¿¡ ºñÇØ ¡°½Å»ý¹°¡±Àº ½Åü³» ¾ø´ø °ÍÀÌ »õ·Î »ý°Ü³µ´Ù´Â ¶æÀ¸·Î ºÙÀÎ ¸»ÀÌ´Ù. ±×·¯³ª, ÀÌ µÑÀÇ °ü°è¸¦ ¸íÈ®È÷ ±ÔÁ¤ÁþÁö ¾Ê°í ÀÖÀ¸¸ç ´ë°³ °°Àº ¶æÀ¸·Î È¥¿ëµÈ´Ù. ½Å»ý¹°¿¡´Â ¡°¾ç¼º(benign)¡±°ú ¡°¾Ç¼º(malignant)¡±ÀÌ ÀÖ´Ù. ÀÌ µÑÀÇ ±¸º°Àº ¿©·¯ °¡Áö ±âÁØ¿¡ µû¸£Áö¸¸, ¶§·Î´Â ±¸º°ÀÌ ¾î·Á¿ï ¶§µµ ÀÖ´Ù. ´ë°³ ¾ç¼ºÀº »ý¸í´ÜÃàÀ» Àß ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î Ä¡·áÈÄ¿¡ Àç¹ßµµ Àß ÇÏÁö ¾Ê´Â´Ù. ÀÌ¿¡ ºñÇØ ¾Ç¼ºÀº Àç¹ß»Ó¸¸ ¾Æ´Ï¶ó ´Ù¸¥ ±â°üÀ¸·Î ¿Å°Ü°¡¼ °°Àº º´º¯ÀÌ ¹ß»ýÇÏ´Â ¡°ÀüÀÌ(metastasis)¡±Çö»óµµ ÀϾÙ. µû¶ó¼ »ý¸íÀ» ´ÜÃà½ÃŰ´Â °æ¿ì°¡ ¸¹À¸¸ç, ´ë°³ Ä¡·á°¡ ¾î·Æ´Ù. |
||
| ¿µ¹® | TNM staging system | ÇÑ±Û | Á¾¾çº´±âºÐ·ù°èÅë |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ º´±â(stage)¸¦ °áÁ¤ÇÏ´Â ÇÑ ¹æ¹ý. T´Â Tumor(Á¾¾ç)¸¦ ¶æÇÏ¸ç ¿ø¹ßº´ÅÍÀÇ Å©±â, ÁÖÀ§Á¶Á÷À¸·ÎÀÇ Ä§À±Á¤µµ µî¿¡ µû¶ó T1, T2, T3, T4(¼ýÀÚ°¡ ³ôÀ» ¼ö·Ï ÁÖÀ§·Î ħÀ±ÀÌ ¸¹´Ù) µîÀ¸·Î ³ª´«´Ù. NÀº Node(¸²ÇÁÀý)¸¦ ¶æÇϸç ħ¹üµÈ ¸²ÇÁÀýÀÇ °¹¼ö, Å©±â, À§Ä¡ µî¿¡ µû¶ó N1, N2, N3 µîÀ¸·Î ³ª´«´Ù. MÀº Metastasis(ÀüÀÌ)¸¦ ¶æÇÏ¸ç ¿ø°ÝÀüÀÌÀÇ À¯¹«¿¡ µû¶ó M0, M1 µîÀ¸·Î ³ª´«´Ù. ÀÌ»óÀÇ ¹æ¹ýÀ¸·Î T, N, MÀÌ °áÁ¤µÇ¸é À̵éÀ» Á¶ÇÕÇÏ¿© ÃÖÁ¾ÀûÀÎ º´±â¸¦ °áÁ¤ÇÑ´Ù. ÀÌ·¸°Ô °áÁ¤µÈ º´±â´Â Ä¡·á ¹æÄ§ °áÁ¤°ú ¿¹ÈÄ ÆÇ´Ü¿¡ ¸Å¿ì Áß¿äÇÏ´Ù. |
||
| ¿µ¹® | staging of tumors | ÇÑ±Û | Á¾¾çÀÇ º´±â |
|---|---|---|---|
| ¼³¸í | º´±â´Â Á¾¾çÀÇ ÆÄ±ÞÁ¤µµ ¹× À§Ç輺À» ÀÏÁ¤ÇÑ ±âÁØ¿¡ ÀÇÇØ Ç¥½ÃÇÏ´Â ¹æ¹ýÀ¸·Î¼ ÀÓ»óÀû, ¿Ü°úÀû, º´¸®ÇÐÀûÀÎ ¹æ¹ý¿¡ ÀÇÇØ ½Ç½ÃÇÏ¿© Æò°¡ÇÑ´Ù. º´±âÀÇ ±¸Ã¼Àû ¸ñÀûÀº Ä¡·áÀÇ °èȹÀ» ¼¼¿ì´Âµ¥ µµ¿òÀÌ µÇ°í, ¿¹ÈÄ¿¡ ´ëÇÑ ÁöħÀ» Á¦½ÃÇÏ´Â µ¥ ÀÖ´Ù. ¶ÇÇÑ, Ä¡·áÀÇ °á°ú¸¦ Æò°¡Çϴµ¥ µµ¿òÀÌ µÇ¾î¼, Ä¡·áÈÄ ¼·Î Á¤º¸±³È¯À» ¿ëÀÌÇÏ°Ô ÇÏ¿© º¸´Ù ³ªÀº Ä¡·á°èȹ¼ö¸³¿¡ Áß¿äÇÏ´Ù. 1)ÇØºÎÇÐÀû º´±â(anatomic stage): ÀϹÝÀûÀ¸·Î TMNºÐ·ù¸¦ »ç¿ëÇÑ´Ù. Áúº´ÀÇ Ä§¹ü ¹üÀ§¸¦ ¼¼ ºÎºÐÀ¸·Î Ç¥½ÃÇÔ. TÇ׸ñ: Á¾¾çÀÇ ÀÏÂ÷¼º ħ¹ü ¹üÀ§¸¦ Ç¥½ÃÇϸç ÈçÈ÷ Á¾¾çÀÇ Å©±â, ħ¹üÀÇ ±íÀÌ, Ç¥¸é ÀüÆÄ µîÀÇ ¼¼ °¡Áö ÇüÅ¿¡ ±âÃʸ¦ µÒ. NÇ׸ñ: Á¾¾çÀÇ ÀÌÂ÷¼º ¶Ç´Â ¸²ÇÁÀý ħ¹ü ¹üÀ§¸¦ Ç¥½ÃÇÏ¸ç ¸²ÇÁÀýÀÇ Å©±â, °æµµ, ¼ýÀÚ µî¿¡ ±âÃʸ¦ µÒ. MÇ׸ñ: Á¾¾çÀÇ ÀüÀÌ, Áï Ç÷°ü¼º ħ¹ü ¹üÀ§¸¦ Ç¥½ÃÇϸç ÀϹÝÀûÀ¸·Î Áß¿äÇÑ °ÍÀº ÀüÀÌÀÇ Á¤µµ°¡ ¾Æ´Ï¶ó ÀüÀÌÀÇ À¯¹«ÀÓ. 2) Á¶Á÷ÇÐÀû ºÐ·ù: Çö¹Ì°æÀû ¼Ò°ß¿¡ ÀÇÇØ ¾Ï¼¼Æ÷ÀÇ ¾Ç¼º Á¤µµ¸¦ Ç¥½ÃÇÏ¸ç Æ¯È÷ ¿¬Á¶Á÷À°Á¾ÀÇ ¿¹ÈÄ¿¡ Áß¿äÇÔ. ¶Ç ³¼Ò, °íȯ Á¾¾ç µîÀº º´¸®Á¶Á÷ÇÐÀû ºÐ·ù¿¡ µû¶ó Ä¡·á¹æ¹ýÀÌ ´Ù¸£¸ç È£ÁöŲº´°ú ºñÈ£ÁöŲ¸²ÇÁÁ¾ÀÇ ±¸ºÐ¿¡µµ Áß¿äÇÔ. |
||
| TNM staging System | standard Tumor, NOde & Metastasis staging system |
|---|---|
| ISS | International Staging System |
| AJCCS | American Joint Committee on Cancer Staging |
| CSU | casualty staging unit; catheter specimen of urine; central statistical unit; clinical specialty unit... |
| cTNM | TNM (q.v.) staging of tumors as determined by clinical noninvasive examination |
| INSS | International Neuroblastoma Staging System |
|---|---|
| SMN | Second Malignant Neoplasm |
| neoplasm staging | Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. (12 Dec 1998) |
|---|
| avascular necrosis staging | <radiology> Stage CT/X-ray bone scan I - cold/hot spot II sclerotic focus with osteopenic ring III crescent sign (subchondral lucency) IV articular collapse flattening of femoral head sensitivity 86% 78% specificity 79% 75% see also: avascular necrosis (AVN) (12 Dec 1998) |
|---|---|
| malignant melanoma: staging | <radiology> Clark staging: level I: all tumour cells above basement membrane (in situ), level II: tumour extends to papillary dermis, level III: tumour extends to interface between papillary and reticular dermis, level IV: tumour extends between bundles of collagen of reticular dermis, level V: tumour invasion of sucutaneous tissue (87% metastases) Breslow staging: thin: less than 0.75 mm depth of invasion, intermediate: 0.76 - 3.99 mm depth of invasion, thick: greater than 4 mm depth of invasion see: malignant melanoma (12 Dec 1998) |
| renal adenocarcinoma: staging | <radiology> Typical presentation: Haematuria . . . . . 70% Fever . . . . . . . 16% Pain . . . . . . . . 50% Polycythemia . . . . 3% Palpable mass . . . 20% Anatomic staging (TNM): T1 Small tumour, kidney not enlarged T2 Large tumour, contained within renal capsule T3 Extension into perinephric fat or renal vein T4 Invasion of adjacent organs (12 Dec 1998) |
| staging | Staging of breast cancer is based on the TNM Classification which classifies the size, site and spread of the disease.Therapeutic decisions are formulated in part according to staging (they are formulated primarily according to lymph node status and ER and PR receptor levels in the tumourous tissue, refer definition of ER and PR in this dictionary). The numbers I, II, III and IV are used to denote the stages and each number refers to a possible combination of TNM factors. For example: a Stage I breast cancer is defined by the TMN group: T1, N0, M0 which mean:T1 - Tumour is 2cm or less in diameter, N0 - No regional lymph node metastasis, M0 - No distant metastasis. A complete outline of TMN and Staging is available from PDQ, for which refer to the resource centre's listing of information services. (16 Dec 1997) |
| TNM staging | A system of clinicopathologic evaluation of tumours based on the extent of tumour involvement at the primary site (T, followed by a number indicating size and depth of invasion), and lymph node involvement (N) and metastasis (M) each followed by a number starting at 0 for no evident metastasis; numbers used depend on the organ involved and influence the prognosis and choice of treatment. (05 Mar 2000) |
| Jewett and Strong staging | Staging of bladder carcinoma: O, noninvasive; A, with submucosal invasion; B, with muscle invasion; C, with invasion of perivascular fat; D, with lymph node metastasis. (05 Mar 2000) |
| antibodies, neoplasm | Immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens. (12 Dec 1998) |
| antigens, neoplasm | Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. (12 Dec 1998) |
| brain neoplasm | Neoplasms of the part of the central nervous system contained within the cranium. (12 Dec 1998) |
| genes, structural, neoplasm | DNA sequences that code for RNA and for the proteins required for the enzymatic and structural function of neoplastic cells. (12 Dec 1998) |
| mucinous cystic neoplasm of pancreas | <radiology> = macrocystic adenoma of pancreas, cystadenoma / cystadenocarcinoma, M:F = 1:9, 40-60 years of age, malignant or pre-malignant, large mass (mean 12 cm), multilocular cysts, thick septations, tail / body in 85% (unlike adenocarcinoma and microcystic adenoma), hypo-/avascular, Differential diagnosis: panc pseudocyst, ** Cf: microcystic adenoma (12 Dec 1998) |
| histoid neoplasm | Old term for a neoplasm characterised by a cytohistologic pattern that closely resembles the tissue from which the neoplastic cells are derived. (05 Mar 2000) |
| neoplasm | <oncology, pathology> New and abnormal growth of tissue, which may be benign or cancerous. (16 Dec 1997) |
| neoplasm circulating cells | Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumours. (12 Dec 1998) |
| neoplasm: gallium imaging | <radiology> Useful: Hodgkin disease and histiocytic form of NHL poor sensitivity below the diaphragm, Burkitt lymphoma: almost 100% sensitivity, hepatoma: 90% sensitivity, melanoma: 90% sensitivity, leukaemia possibly useful: NHL: good for large and mediastinal lesions, nodal metastases from seminoma and embryonal cell carcinoma: 87% sensitivity, non-small cell lung CA: 85% sensitive not useful: head and neck, GI (especially adenocarcinoma), breast, gynaecological, kiddie tumours see: gallium: indications (12 Dec 1998) |
Synonyms : Staging, Cancer, Staging, Tumor
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|